Milestone Progress Payments Sample Clauses

The Milestone Progress Payments clause establishes a payment structure where the contractor or service provider receives payments upon the completion of specific project milestones. Typically, the contract will outline a series of defined milestones, each associated with a deliverable or achievement, and specify the amount or percentage of the total contract price to be paid when each milestone is met. This approach ensures that payments are tied to measurable progress, incentivizing timely performance and reducing the risk for the client by aligning payments with actual work completed.
POPULAR SAMPLE Copied 2 times
Milestone Progress Payments. (Note – this option shall be considered for predominantly single or grouped dwellings projects.)
View Source
Milestone Progress Payments. The Contractor shall give the Superintendent a notice once any of the Works described in column “A” of the table below have been completed (Payment Claim). The Superintendent shall, within fourteen (14) days of receipt of a Payment Claim, determine (and notify the Contractor of its determination) whether that milestone has been attained, and if so, the amount payable by the Principal to the Contractor, being that portion of the Contract Price mentioned opposite such Works in column “B” of the table (which is inclusive of GST), having taken into account any adjustments in accordance with clause 29.3 (Progress Certificate). If the Superintendent fails to issue a Progress Certificate within fourteen (14) days, the Superintendent is deemed to determined, at the end of the fourteen (14) day period that the milestone has not been attained. Payment of a milestone payment shall be made by the Principal within fourteen (14) days after the issue of the Progress Certificate. If the Works comprises of more than one dwelling, then the milestone described in column “A” of the table below must have been completed for all dwellings before the Contractor can make a Payment Claim under this item (and this is irrespective of whether or not item 11 of this Appendix A permits the Works to be completed in Stages). If the Contract Price is adjusted under the Contract, the amount of the remaining Progress Payments shall be adjusted in the manner reasonably determined by the Superintendent to ensure that there is no underpayment or overpayment of the Contract Price.
View SourceView Similar (3)
Milestone Progress Payments. The Contractor shall give the Superintendent a notice once any of the Works described in column “A” of the table below have been completed (Payment Claim).
View SourceView Similar (2)
Milestone Progress Payments. 12.2.1 A schedule (the “Approved Final Milestone Payment Schedule”) showing the dollar amount associated with each Milestone (the “Incremental Payment Amounts”), and the Calendar Quarter in which the Milestone is scheduled to be completed, is included in Exhibit 9. Exhibit 9 also includes a curve (the “Cash Curve”) based on an original schedule of the cumulative value of Incremental Payment Amounts for Milestones scheduled for completion in each Calendar Quarter. So long as the cumulative total to date of actual Milestone Progress Payments does not exceed the Cash Curve (as is adjusted from time to time by the same Change Order adjustments to the Target Cost and Fee), Contractor is entitled to payment for any completed Milestones irrespective of the number of Milestones or sequence. Notwithstanding, if the Parties mutually agree that, in certain circumstances, it is in the best interest of the Project to allow for increased expenditures, then Owner shall allow for exceeding the Cash Curve or shall otherwise adjust the Cash Curve to a higher level to allow the desired expenditures. 12.2.2 The Approved Final Milestone Payment Schedule shall be used as the basis for preparation of requests for payment, and payment, of progress payments (“Milestone Progress Payments”) to Contractor. Milestone Progress Payments shall be made in accordance with the Milestones achieved under the
View Source

Related to Milestone Progress Payments

  • Development Milestone Payments TriSalus shall pay (or cause to be paid) to Dynavax, in accordance with and subject to the terms of this Section 2.3, Section 2.4 and Section 6.4 (each such milestone, a “Development Milestone”, and each payment in respect thereof, a “Development Milestone Payment”): (i) Upon the successful completion by a Milestone Obligor after the Closing of a [**] study with respect to a Product using PEDD, a payment of [**] US Dollars ($[**]), with such Development Milestone Payment being payable only once (for purposes of the foregoing, successful completion means completion of such study in accordance with the plan for such study); (ii) For the first patient Dosed by a Milestone Obligor in each Phase 1 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iii) For the first patient Dosed by a Milestone Obligor in each Phase 2 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iv) For each Phase 2 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 2 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 2 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (v) For each Phase 3 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 3 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 3 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (vi) Upon receipt by a Milestone Obligor of each Regulatory Approval for any Product for any Indication in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (vii) Upon receipt by a Milestone Obligor for each Regulatory Approval of any Product for any Indication in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (viii) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vi) for receipt of such Regulatory Approval), regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; and (ix) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vii) for receipt of such Regulatory Approval), regardless ​ of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval.

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Sales Milestone Payments Artiva shall make the following one-time, non-refundable and non-creditable sales milestone payments to GCLC when the aggregate annual Net Sales of Products in the Territory first reach the thresholds specified below. Artiva shall notify GCLC promptly of the achievement of each such sales threshold. Each sales milestone payment shall be made by Artiva within [***] days after the end of the calendar quarter in which such sales threshold is achieved. To the extent more than one sales threshold is reached in any given calendar year, then the applicable milestone payment for each such achievement shall be due and owing with respect to such calendar year. For clarification, the total milestone payments payable hereunder if all milestone events are achieved is [***].

  • Milestone Payments (a) In partial consideration of the License, Company will pay to Penn the applicable milestone payment listed in the table below after the first achievement of each milestone event for each Licensed Product. Company will provide Penn with written notice within [**] days after achieving each milestone. Receipt of IND Approval for a Licensed Product $100,000 (Waived) Initiation of Phase II clinical trial for a Licensed Product $100,000 [**] [**] [**] [**] [**] [**] First calendar year in which Sales exceed $[**] [**] First calendar year in which Net Sales exceed $[**] [**] “Initiation” of a clinical trial means dosing the first patient in such trial in accordance with the trial protocol. For the sake of clarity, Milestone Events are cumulative. Achievement of a Milestone Event with respect to a Licensed Product triggers all prior milestones with respect to such Licensed Product unless previously triggered and paid. (b) Notwithstanding anything in Section 3.4(a) to the contrary, if development of a Licensed Product for a particular indication in the Field of Use ceases (a “Failed Product”), and development of a next Licensed Product for the same indication (“Follow-On Product”) subsequently commences or continues, then any of the Milestone Payments previously made by Company in connection with such Failed Product shall be fully creditable against the repeated achievement of such milestone event by such Follow-On Product to achieve such milestone event. In the event that Company files an IND before December 31, 2006, the Milestone Payment for Receipt of IND Approval will be waived by Penn. In the event that Company files an IND after December 31, 2006, but before July 1, 2007, the payment Milestone Payment for Receipt of IND Approval will be reduced to $[**]. In addition, any License Maintenance Fee paid within the same year that one or more Milestone Payments are due will be creditable toward any applicable Milestone Payment payable with respect to any Licensed Product in the Field of Use within a year after the date on which such License Maintenance Fee payment was due. (c) The Milestone Payments set forth in this Section 3.4 shall be payable upon achievement of the corresponding milestone event by Company or any of its Affiliates or sublicensees; provided that any such Milestone Payments payable based upon achievement of the corresponding milestone event by a third party sublicensee shall be subtracted from Sublicense Income for purposes of determining the Sublicense Fees payable to Penn pursuant to Section 3.8.

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and: (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless: (1) it will suffer significant uncompensated economic or operational harm from the delay, (2) attainment of the same milestone has previously been delayed, or (3) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.